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The kallikrein-related peptidase (KLK) family of proteases is involved in many aspects of human 
health and disease. One member of this family, KLK4, has been implicated in cancer development 
and metastasis. Understanding mechanisms of inactivation are critical to developing selective KLK4 
inhibitors. We have determined the X-ray crystal structures of KLK4 in complex with both sunflower 
trypsin inhibitor-1 (SFTI-1) and a rationally designed SFTI-1 derivative to atomic (~1 Å) resolution, 
as well as with bound nickel. These structures offer a structural rationalization for the potency and 
selectivity of these inhibitors, and together with MD simulation and computational analysis, reveal 
a dynamic pathway between the metal binding exosite and the active site, providing key details of a 
previously proposed allosteric mode of inhibition. Collectively, this work provides insight into both 
direct and indirect mechanisms of inhibition for KLK4 that have broad implications for the enzymology 
of the serine protease superfamily, and may potentially be exploited for the design of therapeutic 
inhibitors.
The kallikrein (KLK) gene family is the largest protease gene cluster in the human genome and encodes 15 serine 
proteases that have sequence identity varying from 40–80%, with a high degree of structural similarity around the 
active site1. The KLK proteases are involved in development and normal physiology but have also been implicated 
in cancer progression2. KLK4 is predominantly expressed in basal and secretory cells of the prostate gland with 
lower levels of expression in a number of tissues including breast, ovaries, thyroid, testis and developing teeth3–5. 
Over-expression of KLK4 has been documented in malignant prostate, ovarian and breast tumors and is associ-
ated with metastasis6–8, and mechanisms underpinning resistance to androgen deprivation therapy9. Conversely, 
KLK4 inhibition has resulted in reduced proliferation and spheroid formation in tissue culture based systems10. 
Therefore, developing specific ways of inhibiting KLK4 offers an attractive route for future therapeutic strategies.
The most direct way to inhibit KLK4 is by designing specific active site inhibitors. The Bowman-Birk family 
of protease inhibitors (Bowman-Birk Inhibitors (BBI)) are a class of proteins and peptides found in plants and 
plant seeds, where they are thought to play a role in defense against pathogens11. The smallest BBI described to 
date is sunflower trypsin inhibitor-1 (SFTI-1)12, which has also been found to inhibit other serine proteases, 
including KLK413. SFTI-1 is a 14 amino acid bicyclic peptide (1GRCTKSIPPICFPD14). The backbone cyclization 
coupled with an intramolecular disulfide linkage causes SFTI-1 to adopt a constrained structure in solution14. 
SFTI-1 binds trypsin by mimicking a substrate, where Lys5 inserts into the active site S1 specificity pocket12. Once 
bound, SFTI-1 can be cleaved, but the constrained nature of the SFTI-1 backbone maintains the same structure 
as the original uncleaved bound form, so it is not released. Rather, the bond is re-ligated and exists in equilibrium 
with the cleaved form, thus maintaining occupancy in the active site and prolonged inhibition. This mechanism 
conforms to the principles as outlined by Laskowski and is termed the ‘standard’ mechanism of protease inhibi-
tion15,16. The unique structural and functional properties of SFTI-1 make this backbone an ideal scaffold upon 
which new selectivities can be generated17.
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SFTI-1 has been shown to inhibit KLK4 in addition to trypsin and matriptase12,18. Since the trypsin-SFTI-1 
and matriptase-SFTI-1 protease/inhibitor complexes have been characterized by X-ray crystallography, a struc-
tural context is available to dissect relative potencies12,19. This information has been used to elucidate how a 
re-engineered SFTI-1 has reduced potency for trypsin and matriptase while gaining a 28-fold increased potency 
for KLK413.
Allostery offers another route to KLK4 inhibition. KLK4, like the majority of serine proteases, is tightly reg-
ulated by conformational switches. Serine proteases are synthesized in an inactive zymogen state that has a dis-
torted active site unable to efficiently support catalysis20. Upon cleavage of the propeptide, the new N-terminal 
isoleucine/leucine forms a salt bridge with Asp194 (chymotrypsin numbering used throughout the paper) to 
rigidify the oxyanion hole and active site catalytic triad. While most proteases are fully activated upon cleavage of 
the zymogen, some proteases use additional conformational switches such as ions or protein binding partners21,22 
that also alter the rigidity of the active site. The Ile16 residue of KLK4 was previously shown to be released upon 
incubation with metals, consistent with an inhibitory role based upon formation of a destabilized, zymogen-like 
active site23. Since the metal-binding and active sites are separated by more than 20 Å, an allosteric mode of inhi-
bition has been proposed but is not understood.
In order to investigate further both direct and indirect mechanisms of KLK4 inhibition here we describe 
the structures of KLK4 in complex with SFTI-1, an engineered SFTI-1 variant, and with nickel (KLK4-Ni). The 
very high resolution (~1.0 Å) of the KLK4-SFTI-1 structures provides exquisite detail of KLK4-inhibitor inter-
actions and a structural rationalization for inhibitor potency and selectivity. Analysis of the KLK4-Ni structure 
reveals conformational heterogeneity, as well as metals bound at the active site and at an indirect inhibitory site. 
Combining this structure with molecular dynamics simulations depicts an indirect mechanism of information 
transfer resulting in active site inhibition. Collectively, this work provides insight into direct and indirect inhibi-
tion of KLK4 that has broad implications for the enzymology of serine proteases.
Results and Discussion
Structural rationalization of direct KLK4 inhibition by SFTI-1. We previously showed that SFTI-1 
potently inhibits KLK4 proteolytic activity13,24. To examine the interaction between KLK4 and inhibitor we 
determined the X-ray crystal structure of a KLK4-SFTI-1 complex to 1.0 Å resolution. The inhibitor structure 
is well-resolved except for missing density in the backbone of Pro13 and the side chain of Asp14. The contact 
β -sheet of SFTI-1 has multiple interactions with the KLK4 active site, including the P1 Lys5 inserting into the S1 
pocket of KLK4 (Fig. 1B).
Interface interactions are dominated by only 4 SFTI-1 residues: P1 Lys5, P4 Arg2, P2′ Ile7, and Phe12 (Fig. S1A 
& Table S1). Calculating the accessible surface area per residue that is buried upon interaction shows high com-
plementarity between P4-P1′ (Fig. 1C & Table S1). SFTI-1 engages in 10 H-bonds and 2 salt bridges with KLK4 
(Fig. 1B & Table S1). 8 of the H-bonds are mediated by the backbone of SFTI-1. The P1 residue Lys5 is the anchor 
residue since it engages in 4 H-bonds and 2 salt bridges, with its side-chain engaging in 1 out of 5 H-bonds 
and both salt bridges. The only other side-chain interaction is via Arg2. The interaction between protease and 
substrate-like inhibitors is mediated by 8 surrounding loops that are present in all S1 family proteases, dictating 
substrate specificity (Fig. 1A)25. The KLK4 buried surface area in the KLK4-SFTI-1 structure is contributed by all 
loops except loop III (Fig. 1C & S1B).
Conformational changes upon binding SFTI-1. Overall, structural changes upon SFTI-1 binding are 
relatively minor when compared to the structure of KLK4 complexed with the inhibitor p-aminobenzamidine 
(PABA; PDB: 2BDG23; Root Mean Square Deviation (RMSD) = 0.345 Å and 0.338 Å for all backbone atoms, 
and backbone atoms of residues within 5 Å of SFTI-1, respectively; Fig. 1D). However, some specific active site 
changes are seen. Met151 (loop V), adopts two rotamers that both interact with the sidechain of P2′ Ile7 (Fig. 2B). 
To enable the hydrophobic environment of the S4 pocket to accommodate the positively charged P4 Arg, both 
loop VI Leu175 and the adjacent helix Leu171 shift, accompanied by recruitment of a water molecule that makes 
bridging H-bonds between P4 Arg and Tyr172 (loop VI) (Fig. 2A). Outside of the P4-P2′ residues, Phe12 which 
contributes 12% of the SFTI-1 buried surface area (Fig. S1A), induces changes in the conformations of loop IV 
(Fig. 2C). Notably, loop IV residues Asn95, Leu98 and Leu99 all adopt new side chain rotamers (Fig. 2C). These 
structural differences are indicative of conformational selection/induced fit upon SFTI-1 binding.
SFTI-1 is a better fit for trypsin and matriptase than KLK4. When comparing the structure of SFTI-1 
in the context of trypsin, matriptase and KLK4, differences in the interface correlate to the potency of inhibition. 
While there is a discrepancy in the various SFTI-1 inhibition constants reported12,26,27, KLK4 is thought to be the least 
potently inhibited13. Comparison of the structures provides arguments to support this lowered inhibition. SFTI-1 
has less buried surface area and fewer interactions with KLK4 than with either trypsin or matriptase (Table S1). 
SFTI-1 behaves as a Laskowski inhibitor, interacting with its targets following the classical lock-and-key 
model14,17. Indeed, for both trypsin12,28 and matriptase19,29,30 the final bound structures of inhibitor and protease 
each resemble the unbound states. In contrast, KLK4 undergoes significant conformational change at the P4/S4 
site to accommodate SFTI-1 (Fig. 2A). A structural comparison of SFTI-1 complexed to KLK4, trypsin and 
matriptase (overall comparison between the three protein-SFTI complexes is shown in Fig. 3A) shows that one 
cycle of the bicyclic SFTI-1 aligns well (Thr4-Ile10) while the other half shows differences (Fig. 3B). Pro13 and the 
carboxylate of Asp14 have missing density in the KLK4 structure, yet are well-resolved in the context of trypsin 
and matriptase, showing evidence of mobility in the bound state. Second, in the KLK4 complex, rotation of the P4 
Arg2 sidechain shifts its terminal guanidino group more than 7 Å relative to the other two complexes (Fig. 3C–E). 
This P4 Arg2 side chain movement in the context of KLK4 is associated with movements in loop VI (Fig. 2A). 
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Taken together, decreased buried surface area, fewer interactions, and conformational adjustment of the pro-
tease31 are all consistent with a decreased inhibition of KLK4 compared to trypsin and matriptase.
Rationalization of potency of SFTI-1FCQR derivative. We previously tested the amidolytic activity 
of KLK4 against a focused library of synthetic tetrapeptide substrates with an invariant P1 Arg13. KLK4 dis-
played the highest activity for the FVQR-p-nitroanilide (pNA) substrate, with P4 and P2 residues affecting activ-
ity the most13. This sequence was grafted onto the SFTI-1 scaffold with the retention of the cysteine, creating 
SFTI-1FCQR (SFTI-1 substituted with Phe2, Gln4 and Arg5), and resulted in a 18-fold increased inhibition of 
KLK4 (Ki = 3.59 nM)13. To investigate the structural basis for increased potency, we solved the crystal structure 
of a KLK4-SFTI-1FCQR complex to 1.3 Å resolution. Compared with KLK4-SFTI-1 there is an overall increase 
in the buried surface area and number of protease-inhibitor interactions (Table S3 & Fig. S2), consistent with 
the increased inhibitory potency of SFTI-1FCQR. Binding can be mainly attributed to improved interactions at 
mutated residues P4, P2 and P1 (Fig. 4). At the S4 site, the KLK4-SFTI-1FCQR structure shows conformational 
selection and/or induced fit upon binding, where the replacement of Arg at P4 with Phe is associated with a move-
ment of loop VI towards the inhibitor, suggesting an improved interaction (Fig. 4A). Deep in the S2 pocket, the 
KLK4-SFTI-1FCQR structure shows an interaction between Gln4NE of SFTI-1FCQR and Tyr94O of KLK4 (Fig. 4B). 
While there is still a requirement for hydrophobic interactions in the shallow of the S2 pocket, this observation 
provides a structural explanation for why the polarity of Gln is desirable in the S2 pocket, and goes some way to 
explaining the preference for Gln>Val>Leu>Thr at the S2 subsite previously reported13. There are also several 
secondary effects that contribute to improved binding at unchanged SFTI-1 residues, notably P2′ (Fig. 4C & S2, 
Table S3) and Phe12 (Fig. 4D & S2, Table S3). These secondary effects are seen as unbroken density for Pro13 and 
Asp14, which can now be fully resolved, in contrast to KLK4-SFTI-1. Therefore, increased potency of SFTI-1FCQR 
can be rationalized by improvements in binding interactions coupled with favourable conformational changes.
Figure 1. Overview of the KLK4-SFTI-1 interaction. (A) KLK4 with SFTI-1 bound in the active site. The 
backbone and interacting sidechains of SFTI-1 in the active site are shown as black sticks. KLK4 loops I-VIII 
are highlighted and labelled. Modelled SFTI atoms with missing density are transparent; (B) Close-up of 
KLK4-SFTI-1 interactions. KLK4 Salt-bridges and H-bonds are shown as broken magenta lines; (C) Surface of 
KLK4, colored by percentage surface burial upon SFTI-1 interaction (white-red gradient). Interacting SFTI-1 
sidechains are shown as sticks; (D) Structural alignment of KLK4-SFTI-1 with KLK4-PABA23; PDB: 2BDG), 
highlighting differences.
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Structure of KLK4-Ni complex reveals previously hidden dynamics. Structural and mutagenesis 
data showed that KLK4 can be inhibited by a Ni2+ ion binding to residues more than 20 Å from the active site23. 
The KLK4-PABA structure contained 3 nickel ions bound in three separate remote sites (Fig. 5A). Mutagenesis 
experiments showed that mutation of the nickel-chelating residues His25 or Glu77 in one of the sites com-
pletely abolished metal mediated inhibition23. To gain more insight into this mode of inhibition, we crystallized 
KLK4 under identical conditions but in the absence of PABA inhibitor. The resulting 2.3 Å resolution structure 
(KLK4-Ni), a dimer in the asymmetric unit, contains a nickel ion bound to the His25/Glu77 site, but not to either 
of the previously reported loop I sites (Fig. 5B–D). We also show for the first time that in the absence of PABA, 
a nickel ion is bound to KLK4 catalytic residues His57 and Ser195, stabilized in the crystal by interactions with 
Gln183 of two symmetry-related molecules. It is therefore unlikely that this nickel site is physiologically relevant. 
All four nickel positions were validated by an anomalous difference electron density map calculation.
Inspection of B-factors together with discontinuous regions of electron density in loop III suggests that the 
KLK4-Ni structure is more flexible than the KLK4-PABA structure (Fig. 6A). Loop III flexibility is also consistent 
Figure 2. KLK4-SFTI-1 interactions. (A) Comparison of S4 subsites in KLK4-PABA (transparent) and KLK4-
SFTI-1 (solid). SFTI bonds are shown as black sticks, H-bonds as broken lines, water molecules as red spheres; 
(B) Interactions at the S2′ site. The two rotamers of Met151 are shown; (C) SFTI-1 Phe12 is associated with a 
shift in KLK4 loop IV.
www.nature.com/scientificreports/
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with missing electron density for loop III residues 74–75 and 73–74 in chains A and B respectively, even in 
the presence of stabilizing crystal contacts. Thus, as previously suggested23, without the stabilizing influence 
of the PABA active site inhibitor, the increased flexibility of the KLK4-Ni structure enables it to sample new 
conformations.
It has been shown that binding of a metal to the His25/Glu77 site alters the equilibrium of Ile16 insertion, and 
that this site is responsible for the metal-mediated inhibition of KLK4, since H25A or E77A mutants are no longer 
inhibited by metals23. With nickel bound to this site, we observe discrete structural heterogeneity in the active site 
of the KLK4-Ni structure; the Asn192-Gly193 peptide bond can be modelled in two conformations: a canonical 
conformation where the carbonyl of Asn192 forms a H-bond with the backbone of Leu143, and a non-standard, 
flipped Asn192 peptide bond with a loss of this H-bond (Fig. 6B). This non-standard orientation has also been 
noted in other serine protease structures32–37 and is chemically inhibitory since it negates the stabilizing effect of 
the oxyanion hole on the tetrahedral intermediate during catalysis. In addition to direct effects on catalysis, we 
propose loss of the Asn192-Leu143 H-bond will increase the dynamics of Leu143, and destabilize its interaction 
with Ile16, shifting structural equilibrium towards Ile16 release.
The simultaneous finding of flexibility in loop III adjoining the His25/Glu77 inhibitory metal binding 
site and inhibitory conformations at the active site suggests a correlation between these sites. Furthermore, 
Figure 3. Comparison of protease-SFTI-1 complexes for trypsin, matriptase and KLK4. (A) Structural 
overlay of proteases. SFTI-1 backbone and P1 sidechain is shown in the active site for context. (B) Overlay of 
SFTI-1 (trypsin-SFTI-1 = charcoal, matriptase-SFTI-1 = grey, KLK4-SFTI-1 = silver) showing KLK4 surface 
for context. Close-ups of the S4 interactions with (C) trypsin, (D) matriptase, and (E) KLK4. In both trypsin 
and matriptase, Arg2 of SFTI-1 interacts with the backbone of loop IV. In KLK4, loop IV occupies a different 
(folded-over) conformation, Leu175 of loop VI shifts towards loop IV, and so the major interaction of Arg2 is 
with loop VI.
www.nature.com/scientificreports/
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Figure 4. KLK4-SFTI-1FCQR interactions. (A) P4 Phe at the S4 site is concomitant with a shift in the backbone 
of loop VI (solid), towards the inhibitor, compared to when S4 is empty (KLK4-PABA, transparent), or paired 
with Arg2 (KLK4-SFTI-1, transparent); (B) Mutation of P2 Thr4 (KLK4-SFTI-1, transparent) to Gln4 (KLK4-
SFTI-1FCQR, solid) results in an increased buried surface area and allows a H-bond (broken line) with Tyr94. 
The conformation of loop IV is invariant across all structures, including KLK4-PABA (transparent); (C) P2′ Ile7 
occupies different rotamers in KLK4-SFTI-1FCQR (solid) and KLK4-SFTI-1 (transparent). The presence of two 
rotamers of Met151, in both KLK4-SFTI-1 and KLK4-SFTI-1FCQR, indicate conformational frustration at the S2′ 
site; (D) Phe12 shifts more than 2 Å compared with KLK4-SFTI-1 (transparent), and is associated with a lower 
buried surface area for Phe12 in the SFTI-1FCQR structure. To accommodate the high burial in KLK4-SFTI-1 
(transparent), Leu98 is displaced by 1.8 Å from the unoccupied KLK4-PABA conformation (not shown). It 
resumes the unoccupied conformation in KLK4-SFTI-1FCQR (solid).
www.nature.com/scientificreports/
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loop III shows the highest degree of structural diversity when comparing KLK4-PABA, KLK4-Ni, KLK4-SFTI-1 
and KLK4-SFTI-1FCQR structures (Fig. 6C). Since the presence of active site ligands is known to alter the dynam-
ics of serine proteases38,39 we suggest H25/E77-loop III and the active site are hubs of information transfer that 
regulate KLK4 activity depending upon ligand state.
MD simulations reveal widespread changes in dynamics upon metal binding, hindering sub-
strate access to the active site. Intrigued by how the His25/Glu77 metal binding site more than 20 Å 
from the active site indirectly inhibits proteolytic activity, we performed MD simulations of KLK4 in the presence 
and absence of nickel bound at this site. In the His25/Glu77 nickel-free KLK4 (KLK4-apo) simulation, loop III 
exhibits the most flexibility, compared to the rest of the molecule (Fig. 6E). Thus, MD simulations are consistent 
with conformational flexibility in loop III, as indicated by crystal structural analysis of KLK4-Ni, as well as the 
structural diversity amongst KLK4 structures. In simulations of the His25/Glu77 Ni-bound structure, despite 
preserving overall flexibility in loop III, the Glu77-Ni-His25 interaction is associated with a reduction in mobility 
(Fig. S3B). We also observed a long-range stabilization effect on distant regions such as active site loop II and 
the C-terminal half of loop VIII (Fig. 6E & S3B), associated with Ni2+ binding. In contrast, simulations of the 
Ni-bound structure show increased fluctuations around subsite S3, between Phe215 and Cys220 of loop VIII 
(Fig. 6E). Our simulations therefore suggest that metal binding to the His25/Glu77 site results in local stabiliza-
tion (loop III) that affects overall KLK4 dynamics (loops II and VIII).
By assuming SFTI-1 residues P4-P2′ bind to KLK4 in a similar mode to a natural substrate, we can use the 
KLK4-SFTI structure to model the effect that MD-simulated loop motions would have on substrate binding. 
Superimposing the SFTI-1 structure onto the MD-generated ensemble of KLK4-apo simulations shows that the 
His25 and loop II, III and VIII motions do not interfere with SFTI-1 P4-P2′ binding and would not be inhibitory 
(Fig. 6E). Thus this simulation mostly sampled the non-inhibitory apo state (Fig. 6E). In contrast, SFTI superpo-
sition onto the Ni-bound ensemble reveals significant clashes at active site loop VIII (Fig. 6E). During the simula-
tion timecourse, initially the Phe215 sidechain clashes with the P2/P3 residues of SFTI-1, followed by the 215–217 
segment moving to clash with P1/P2, ending with a flip of Lys217 sidechain to clash with P2/P3/P4. Therefore, 
these simulations show how loop VIII motions would sterically hinder substrate binding when Ni2+ is bound to 
the His25/Glu77 site, offering mechanistic insight into metal-mediated indirect inhibition of proteolytic activity.
Figure 5. Structural comparison of KLK4 crystallized in the presence of 10mM nickel, (A) with 20 mM PABA 
(KLK4-PABA, 2BDG chains A and B) or (B) without PABA (KLK4-Ni). KLK4 is drawn as cartoon and surface. 
S1 pocket is occupied by PABA (sticks) in KLK4-PABA, and a Ni2+ ion (green sphere) in KLK4-Ni, interacting 
with His57 and Ser195 (sticks). KLK4-PABA has two Ni2+ ions bound that are not seen in KLK4-Ni, on both 
sides of loop I. One Ni2+ ion is common between both structures, bound to His25 and Glu77. The KLK4-Ni 
structure is flexible and has missing electron density in loop III as depicted in the circled region; (C) Overlay 
of KLK4-Ni (solid) and KLK4-PABA (translucent). Loops II, IV, and VI–VIII are well aligned; (D) Overlay 
focused on loop III, showing missing electron density. Ni2+ was observed at this site in both structures.
www.nature.com/scientificreports/
8Scientific RepoRts | 6:35385 | DOI: 10.1038/srep35385
Figure 6. KLK4 Dynamics. (A) Normalised B-factor cartoons of KLK4-PABA (2BDG) and KLK4-Ni (4KGA), 
showing chain A alone. B-factors have been normalised within each individual structure. KLK4-PABA has an 
average B-factor of 20.59, and KLK4-Ni chain A has an average B-factor of 65.77; (B) Two conformations of the 
N192-G193 peptide bond in the KLK4-Ni crystal structure. Composite omit map indicates the presence of both 
conformations. 2Fo − Fc maps (grey) are shown at 1σ , composite omit Fo − Fc maps (green) are shown at 3σ . A 
H-bond is shown as long black dashes between D194OD-G142N, a H-bond only present in one conformation 
between N192o-L143N is shown in short black dashes; (C) Loop III is structurally diverse. The structures 
of KLK4-Ni (golden), KLK4-SFTI-1FCQR (brass), KLK4-SFTI (bright yellow) and KLK4-PABA (cream) are 
shown with nickel binding site residues H25 and E77 represented as sticks; (D) Nickel binding shifts the KLK4 
equilibrium populations related to large amplitude motions. (Left) Normal mode coordinates were computed 
www.nature.com/scientificreports/
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Metal-dependent coupled loop dynamics drives long-range communication networks in 
KLK4. In order to explore the effect of metal-binding on large amplitude motions of KLK4 we calculated nor-
mal mode (NM) coordinates for each conformational state explored during the MD trajectories of the KLK4 in 
the presence and absence of nickel. Conformations explored during atomistic MD were projected onto the first 
five low-frequency NMs. With one key exception, the distribution of conformations was centered on the origin, 
showing limited sampling of rigid-body motions during MD (Fig. 6D & S4). However, the presence of nickel 
bound near loop III resulted in a shift in the equilibrium population along mode 8. This global motion links 
loop III (close to the Ni-binding site) with the loops I and VIII near the active site, indicating that Ni-binding 
affects the equilibrium conformation of KLK4. Next, dynamical cross correlation (DCC) coefficients were calcu-
lated for pairs of residues in KLK4 and mapped onto the structure (Fig. 6F). Importantly, loop III motions (near 
the allosteric site) were observed to be linked to those of loop VII residues and active site residues (especially 
Asp194), highlighting dynamic communication between these distant regions. We then investigated the distribu-
tion of energy within the KLK4 structure using a mutational frustration analysis, which explores the influence of 
localized sequence and conformational perturbations on the energetic frustrations40 within the structure. Most of 
the structure shows favorable interactions between residues (Fig. 6G), though both the active site region and loop 
III contain patches of highly frustrated contacts. These distant regions are connected by an intramolecular path 
of frustrated interactions (Fig. 6H), spanning from Glu77 (at loop III) to hubs of localized frustration at Asp102 
and Asp194 in the active site (Fig. 6G). Taken together, this analysis indicates a correspondence between confor-
mational dynamics and energetic frustrations on KLK4, and identifies a network of frustrated residues that may 
form a communication network bridging the Ni-binding site and the active site.
SFTI-1 binding is correlated with reduced dynamics and frustration in loops VI and III. Loop VI, 
which is highly frustrated in the apo form, becomes more stabilized in the presence of SFTI-1FCQR, the more potent 
inhibitor (Fig. S5). The KLK4-SFTI-1FCQR structure shows an alternative loop III conformation to those obtained 
in the KLK4-Ni and KLK4-SFTI-1 structures (Fig. S8A). This single, less-frustrated conformation (Fig. S8C) 
was maintained throughout all simulations of KLK4 with SFTI-1FCQR (Fig. S8B). All other simulations with bound 
inhibitor showed at least two highly-populated states − similar to the distribution for the apo form − showing 
that these bound inhibitors poorly restrict the intrinsic conformational variability in loop III (Fig. S8C). This 
analysis suggests a dynamic interplay between the active site and loop III, supporting the observations that active 
site occupancy is associated with alternate loop III conformations in the crystal structures, and loop III instability 
is associated with non-canonical “inhibitory” conformations when the active site is empty.
KLK4 and factor VIIa share a common metal-binding site. Kallikreins are proteases that perform 
catalysis in organs with high zinc concentrations21. The KLK4 inactivation by nickel described in this work is 
also proposed to apply to zinc binding to the same H25/E77 site23. A molecular understanding of zinc-mediated 
inhibition of members of the kallikrein family is emerging with three types of inhibition seen41. First, in a KLK3 
structure, zinc has been shown to bind Asp91, His101 and His233. This is proposed to inhibit activity by chang-
ing the conformation of catalytic residue Asp10242. Second, zinc binding to residues in loop IV (also known as 
the 99-loop) and the catalytic His57 is proposed to block catalysis for rKLKL1c243, KLK544 and KLK745. KLK4 
is unique among the kallikreins in its mode of zinc-mediated inhibition through metal binding residues His25 
and Glu77 in loop III. However, it has been noted previously that there are similarities between KLK4 and Factor 
VIIa with regards to allosteric inhibition by zinc21. FVIIa, when not bound to tissue factor, is inhibited by zinc 
but can reverse this inhibition with calcium46,47. A structural comparison between FVIIa33 and KLK4 reveals the 
structural equivalence of one (“site-2”) of the two zinc sites of FVIIa with the Ni/Zn His25/Glu77 site of KLK4 
(Fig. S9). Therefore, both proteases feature a metal bridge between the N-terminal strand (at Lys24) and loop III. 
Since FVIIa also has a calcium ion that is chelated by loop III, we speculate that the calcium binding site in loop 
III is required for stability — without calcium, loop III movements could send site-2-dependent inhibitory signals 
to the active site, while calcium binding would stabilize loop III and reverse this inhibition. Thus we propose that 
KLK4 and FVIIa share similar mobile loop III/metal bridge allosteric inhibitory mechanisms.
Conclusions
KLK4 has been crystallized in the presence of SFTI-1 and an engineered SFTI-1 derivative. These structures allow 
detailed insights into the interactions that occur between the active site and inhibitors, enabling more specific 
inhibitors to be designed for KLK4. Furthermore, our KLK4-Ni structure shows an inhibitory conformation for 
for each conformational state explored during the MD trajectories of KLK4-apo (black) and KLK4-Ni (red); 
(Right) cartoon representation of the most populated states showing that despite the distance from the Ni 
binding site (highlighted by its coordinating residues His25 and Glu77 in sticks), regions close to the active 
site (dashed circle) undergo noticeable conformational rearrangements; (E) Superposition of MD snapshots 
for KLK4 with and without Ni at the His25/Glu77 site. Snapshots at 1 ns intervals from the MD simulation of 
KLK4 without Ni (KLK4-apo, left) and with Ni (KLK4-Ni, right) are presented, SFTI is shown in the active 
site for context, but was not present in simulations; (F) Dynamical cross correlations (C(i,j)) calculated from 
motions contributed by the first 40 low frequency normal modes, plotted onto the KLK4-Ni structure. Red 
and blue edges connect pairs of residues that are correlated or anticorrelated, respectively; (G) Visualization 
of the frustration networks mapped onto the KLK4 structure. Minimally and highly frustrated contacts are 
represented in green and red, respectively; (H) Visualization of the intramolecular path of highly frustrated 
residues, connecting loop III (in yellow) to the active site region.
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the 192–193 peptide bond, an active site-bound metal and implies loop III has instability/flexibility that has not 
been previously reported23. We propose that loop III flexibility is a key component in the indirect regulation of 
KLK4. This hypothesis is interesting from an evolutionary perspective. During evolution from ancestral trypsin48, 
KLK4 sacrificed some stability by mutation of an existing calcium-binding loop III while also acquiring a bridge 
for transferring instability in the form of an His25/Glu77 metal binding site. These molecular features would be 
favoured in the zinc- and calcium-rich environments of developing teeth2 in order to regulate KLK4 activity. 
Therefore, KLK4 divergence from ancestral trypsin is an adaptation to the specialized environments involved in 
development. Collectively, these studies offer insight into the structure and function of inhibition for the serine 
protease superfamily.
Materials and Methods
Protein expression, refolding and purification. Using the previously reported pET12-proPSA-hK4 
chimera plasmid49, KLK4 was expressed in E. coli as inclusion bodies. The subsequent purification and refolding 
methods are described in detail in SI Methods.
Synthesis of SFTI-1 variants. Inhibitory peptides were synthesized on 2-chlorotrityl resin (1.55 mmol/g, 
Iris Biotech) with 9-fluorenylmethyl carbamate as semi-permanent protecting group using a Discover SPS 
Microwave System (CEM Corporation) to enhance conventional solid phase peptide synthesis. Peptide cyclisa-
tion was carried out in solution also using microwave enhancement as previously described17.
Inhibition assays. Inhibition of KLK4 by SFTI-1 was assessed in competitive inhibition assays, and the inhi-
bition constant (Ki) was determined by non-linear regression in GraphPad Prism (Morrison equation), as recently 
described17. Assays were performed three times in triplicate in 96-well low-binding plates (Corning) using 1.5 nM 
KLK4 and 120 μ M FVQR-pNA in 250 μ L assay buffer (0.1 M Tris-HCl pH 7.4, 0.1 M NaCl, 0.005% Triton X-100).
Crystallization. All crystals were grown using the hanging drop vapor diffusion method, with 1:1 (v/v) ratio 
of protein to mother liquor.
KLK4-Ni. Crystallization conditions for KLK4 in complex with p-aminobenzamidine (PABA)23 were used as a 
guide for crystallizing KLK4-Ni in absence of PABA. A gradient of 10–30% of PEG 2000 and Tris-HCl pH 7.5–9.0 
was used for initial screening with KLK4 concentration at 10 mg/mL. Final crystals were grown at 18 °C using 
4 μL drops equilibrated over 1 mL of 20% PEG 2000, 100 mM Tris pH 8.0, 10 mM NiCl2 buffer.
KLK4-SFTI-1 and KLK4-SFTI-1FCQR.  Prior to crystallization experiments of the KLK4-SFTI-1 and KLK4-SFTI-1FCQR 
complexes, 20 mg/ml protein was incubated overnight with 3-fold molar excess of inhibitor (solubilized in 25% 
acetonitrile to the working concentration of 100 mM) at 4 °C. In order to identify initial hits, commercially avail-
able screens including Index (Hampton Research), JCSG+ and PACT (Qiagen) were used50. The crystallization 
trials were set up manually at 18 °C utilizing hanging drop vapor diffusion method. Final KLK4-SFTI-1FCQR crys-
tals were obtained within a week by mixing 2 μL of protein-peptide solution with equal volume of crystallization 
buffer (0.1 M Li2SO4, 0.1 M sodium acetate, 30% PEG 8000, pH 4.6) and equilibrated at 18 °C. KLK4-SFTI-1 crys-
tals were produced by mixing 2 μL of protein-peptide solution and 2 μL of reservoir buffer (0.2 M Li2SO4, 0.1 M 
sodium acetate, 20% PEG 8000, pH 4.8) and appeared after 9 months of incubation at 18 °C.
X-ray data collection, structure determination and refinement. All datasets were collected at the 
Australian Synchrotron, Victoria, Australia on MX151 (KLK4-Ni) and MX2 (KLK4-SFTI complexes) beamlines 
using the Blu-Ice software52. More detail can be found in SI Methods. Structure determination proceeded using 
the molecular replacement method and the program PHASER53. A search model was constructed from the crys-
tal structure of KLK4 in complex with PABA23 (PDB: 2BDG, chain A) by removing solvent molecules and lig-
ands. All subsequent model building, refinement and structural validation was done using Phenix54 and COOT55. 
Composite omit maps (Fig. 6C) were calculated using Phenix54. An anomalous difference map was created for 
the KLK4-Ni structure (using anomalous difference structure factor amplitudes and phases generated from the 
refined structure with heavy atoms removed). Four peaks were observed on this map at between 4.3 to 4.8 σ , sup-
porting the positions of the Ni atoms. A summary of statistics is provided in Table 1.
Structure analysis. For all analysis and MD simulations, missing atoms, side chains and residues were 
rebuilt using Modeller v9.1056. In each instance, 50 models were built and the lowest DOPE (Discrete Optimized 
Protein Energy) scoring model was selected for further analysis. Hydrogen bonding and salt bridge values 
were calculated using the PISA web-server57. Solvent accessible surface area was calculated using AREAIMOL 
as part of the ccp4 package with a default probe radius of 1.4 Å58. Structural comparisons between KLK4, 
SFTI-1 and related serine proteases discussed in the text were performed after a global backbone alignment 
using the following PDB entries: SFTI-1 NMR structure (1JBL), KLK4-PABA (2BDG), trypsin-SFTI-1 (1SFI), 
trypsin-benzamidine (2BLV), matriptase-SFTI-1 (3P8F), matriptase-benzamidine (1EAX) and ligand-free 
matriptase (4IS5). Comparisons to determine structural changes induced/selected by SFTI-1 binding were per-
formed by inspection of structural deviations between SFTI-1 bound and corresponding benzamidine/PABA 
bound proteases structures. When 3 consecutive residues or more were found to have more than 0.5 Å Cα devi-
ation, this deviation was then compared against a third structure with an unliganded active site. If the deviation 
was only seen in the SFTI-1 structure (determined statistically by comparing values in a two-tailed T-test), the 
structural change was marked as being induced/selected by SFTI-1.
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Computational resources. Calculations, modeling and simulations were performed on a range of com-
puting resources: ORCHARD 800 core x86 cluster (Monash University; X-ray ensemble refinement); AVOCA/
MERRI (VLSCI BlueGene/Q/x86 cluster; atomistic MD).
Atomic coordinates, modeling and graphics. In MD simulations, atomic coordinates were obtained 
from the following PDB entries: 4KGA (chain A), 4K8Y & 4K1E. Missing residues and atoms were rebuilt using 
MODELLER version 9.1056. All structural representations were produced using PyMOL version 1.7.659 and 
VMD 1.9.260, and all trajectory manipulation and analysis was performed with a combination of custom scripts, 
MDTraj61, SciPy62, Matplotlib63, iPython64 and VMD 1.9.260.
Molecular dynamics (MD) systems setup and simulation. Each protein, with protonation states 
appropriate for pH 7.065,66, was placed in a rectangular box with a border of at least 12 Å, explicitly solvated 
with TIP3P water67, counter-ions added, and parameterized using the AMBER ff14SB all-atom force field68–70. 
Harmonic restraints were added to maintain the Ni2+ ion bound at the His25 and Glu77 site.
After an energy minimization stage, and an equilibration stage, production simulations were performed in the 
NPT ensemble. Three independent replicates of each system were simulated for 200 ns each using NAMD 2.971. 
More details are available in SI Methods.
Normal mode calculations. The normal modes of KLK4-apo were calculated with CHARMM 3772 
software in conjunction with the AMBER ff99SB forcefield73. Calculations were performed in vacuum using a 
distance dependent dielectric constant (ε = 2ri,j), to treat electrostatic interactions. Prior to NM calculations, 
the KLK4-apo structure was energy minimized using the steepest descent (SD) and conjugate-gradient (CG) 
methods followed by the Adopted Basis Newton-Raphson (ABNR) algorithm. The energy minimized structure 
presented 0.7 Å RMSD (backbone atoms) against the crystallographic conformation. Harmonic restraints were 
applied during the SD steps and were progressively decreased from 250 to 0 kcal mol−1 Å−2. Then, the system was 
further energy minimized with 1000 CG steps and the ABNR algorithm applied without positional restraints 
using a convergence criterion of 10−5 kcal mol−1 Å−1 RMS energy gradient. The first 100 low frequency normal 
modes and the atomic fluctuations were computed with the VIBRAN module of CHARMM. The first five low 
frequency NMs (Movie S1) accounted for 68% of overall KLK4 dynamics.
Data collection KLK4-SFTI-1 KLK4-SFTI-1FCQR KLK4-Ni
Wavelength (Å) 0.8266 0.9537 0.9537
Space group P1211 P1211 P4
Unit cell dimensions  
a, b, c (Å), α , β , γ (°)
31.93, 75.75, 39.74  
90, 95.73, 90
39.78, 63.31, 41.18 
90, 115.66, 90
99.31, 99.31, 41.02 
90, 90, 90
Resolution (Å) 29.3-1.0 37.1-1.30 70.22-2.32
Number of measured reflections 400653 159204 123253
Number of unique reflections 100687 45068 17693
Completeness (%) 99.5 (99.6) 99.6 (100.0) 100.0 (100.0)
Redundancy 4.0 (3.9) 3.5 (3.4) 7.0 (5.8)
Rpim 0.054 (0.253) 0.053 (0.188) 0.039 (0.359)
CC1/2 0.998 (0.869) 0.990 (0.807) 0.475 (0.280)
< I/σ I> 8.7 (2.7) 9.6 (4.2) 12.9 (2.1)
Structure refinement
 Number of reflections 100641 45043 17689
 Number of protein atoms 1924 1798 3214
 Number of water molecules 326 115 56
 Rwork (%) 15.0 14.0 22.0
 Rfree (5% of data) (%) 17.0 17.0 26.4
 RMSD bond lengths (Å) 0.006 0.008 0.003
 RMSD bond angles (°) 1.21 1.16 0.91
 Average B-factor (Å2)
   Protein 10.121 12.306 66.026
   Inhibitor 13.328 18.399 —
   Solvent 21.848 19.456 54.708
 Ramachandran
   Favoured (%) 98.82 97.53 97.95
   Outliers (%) 0 0 0
 MolProbity score 0.86, 99th percentile (N = 666, 1.00 Å ± 0.25 Å)
0.79, 100th percentile 
(N = 2276, 1.30 Å ± 0.25 Å)
1.37, 100th percentile 
(N = 8665, 2.32 Å ± 0.25 Å)
 PDB ID 4K8Y 4K1E 4KGA
Table 1.  Data collection and refinement statistics1. 1Values in parentheses are for high resolution shell.
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Dynamical cross correlation analysis. Rotational and translational degrees of freedom were removed 
by global backbone alignment. Following this, dynamical cross correlation coefficients between pairs of residues 
were calculated considering a set of 100 NMs using the R program with the bio3D package74.
Local Frustration Analysis. Local frustration analysis was conducted with the Frustratometer web server75. 
Briefly, the energetic frustration is obtained by the comparison of the native state interactions to a set of generated 
“decoy” states where the identities of each residue are mutated. Each contact is defined as “minimally frustrated” 
or “highly frustrated” upon comparison of its frustration energy with values obtained from the decoy states as 
described40.
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